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Summary Two hundred and twenty patients with progressive advanced breast cancer were given primary
endocrine treatment (PET) according to menstrual status. Pre-menopausal patients received ovarian irradia-
tion (0) and post-menopausal tamoxifen 10mg bd (T). Patients were randomised to receive either no
additional treatment or prednisolone 5mg bd (P). Similar results were observed in each menstrual subgroup.
In 194 evaluable patients, the response to PET +P was 49% and to PET alone 30% (P<0.01). P increased the
median duration of response from 9 to 14 months (P<0.002) and the median time to disease progression
from 5 to 9 months (P<0.001). Response to P after 0 or T alone occurred in only 2/62 (3%). Median
survival in patients randomised to receive P at the outset of PET was prolonged by 4 months (P<0.05). The
addition of P significantly improves the response to 0 or T in the treatment of advanced breast cancer.
For some years the preferred primary endocrine treatment
for metastatic breast cancer has been ovarian ablation for
pre-menopausal, and tamoxifen for post-menopausal,
patients. Corticosteroids alsohaveactivityagainst breastcancer
(Minton et al., 1981) but the mechanism ofaction is not known
for certain. It may be mediated by suppression of adrenal
sex hormones and also have a direct action on cancer cells.
When prednisolone was added to adjuvant ovarian irradia-
tion after mastectomy for early breast cancer, it led to a
significant reduction in recurrence rate and improved survi-
val (Meakin et al., 1979).
These observations led to a trial in this Unit to assess the
contribution of prednisolone to the primary endocrine treat-
ment of advanced breast cancer (Stewart et al., 1982). Pre-
menopausal patients with metastatic breast cancer were
randomised to receive ovarian irradiation either alone or in
combination with prednisolone, while post-menopausal
patients received tamoxifen either alone or with predniso-
lone. The corticosteroid significantly improved the response
frequency to primary endocrine treatment and, in post-
menopausal patients, survival was prolonged. It was unclear
from this trial whether using prednisolone sequentially, after
tamoxifen alone, could have achieved similar results. A
further observation was that prednisolone appeared to
prevent the occurrence of hypercalcaemia and tumour 'flare'
sometimes seen with tamoxifen alone. In that trial, the
response to tamoxifen alone was unexpectedly low at 17%
and the conclusion that prednisolone significantly improved
the response frequency was only tentative. Accordingly,
another trial was established to study further the contribu-
tion of prednisolone to primary endocrine treatment. This
trial, in which the addition of prednisolone after failure of
primary endocrine treatment alone is also studied, is
reported here.
Patients and methods
Patients
Eligible patients had progressively locally recurrent and/or
metastatic breast cancer, confirmed histologically and not
controllable by local treatment. The disease was evaluable
according to UICC criteria (Hayward et al., 1977). Patients
had had prior primary treatment by either mastectomy or
tumour excision with radiotherapy for operable disease, or
radiotherapy alone for primary locally advanced inoperable
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disease. Patients who had had adjuvant endocrine treat-
ment were excluded. Patients might have had radiotherapy
to metastatic sites, but none had had previous endocrine
treatment or chemotherapy for recurrent or metastatic
disease.
Steroid receptor information was available for most
tumours. Oestrogen receptor (ER) and progesterone receptor
(PgR) status was deemed positive for values of 5 or more
fmol receptor mg-1 cystosol protein by the method of King
et al. (1979). Patients with tumours positive for one
(ER+PgR- or ER-PgR+) or both (ER+PgR+) receptors
or of unknown receptor status were eligible for the trial;
patients with tumours known to be negative for both
receptors were excluded.
Patients were ineligible for the trial if they were receiving
systemic corticosteroid therapy or if they had done so in the
previous year. They were excluded if there were medical
contra-indications to the use of corticosteroids (e.g., diabetes
mellitus, peptic ulcer) or if there had been previous malig-
nancy other than non-melanomatous skin cancer or ade-
quately treated carcinoma in situ of the cervix uteri.
Potentially eligible patients with concurrent hypercalcaemia
were only eligible if this could be controlled without the use
of corticosteroids. Irrespective of other features of eligibility,
patients in whom immediate chemotherapy was thought
advisable because of rapidly progressing life-threatening dis-
ease (e.g., pulmonary infiltration or liver metastases with
marked elevation of liver enzymes) were excluded.
Menstrual status
Before randomisation, patients were stratified according to
menstrual status in order to determine the appropriate
endocrine therapy.
(a) Patients who had had a menstrual period within the
previous 6 months were regarded as pre-menopausal,
while if the last menstrual period was 6 months ago
or longer, patients were deemed post-menopausal.
(b) Patients with a previous hysterectomy and retention
of one or both ovaries were regarded as pre-
menopausal if less then 50 years of age and post-
menopausal if 50 years or over.
(c) Pre-menopausal patients who ceased menstruating
whilst on adjuvant chemotherapy and then relapsed
whilst receiving, or within 6 months of stopping,
chemotherapy were considered pre-menopausal. If
relapse occurred 6 months or more after stopping
adjuvant chemotherapy, the menstrual status was
assessed as in (a) above.
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Treatment
Pre-menopausal patients were randomised to receive either
(1) ovarian irradiation (1,200-1,500cGy central dose in 4-5
fractions in 4-7 days by opposed fields to the whole pelvis)
with prednisolone 5mgbd starting on the first day of
ovarian irradiation and continued until evidence of progress-
ive disease (O+P); or (2) ovarian irradiation alone (0). On
disease progression, patients receiving 0 alone were pre-
scribed prednisolone 5 mg bd until there was further evidence
of progressive disease. However, if on progression after 0
alone, rapidly progressive life-threatening disease made
immediate chemotherapy advisable, this was instituted
together with corticosteroids.
Post-menopausal patients were randomised to receive
either (1) tamoxifen 10mgbd +prednisolone 5mgbd (T+P),
continued until evidence of progressive disease; or (2)
tamoxifen 10mgbd alone (T), when, on progression of
disease, T was continued and prednisolone 5mgbd added
until there was evidence of further disease progression. If on
progression after T alone, rapidly progressive life-threatening
disease made immediate chemotherapy advisable, this treat-
ment was instituted together with corticosteroids.
As far as possible, treatment on relapse after prednisolone
was standardised. Provided chemotherapy was not con-
sidered necessary, patients were prescribed amino-
glutethimide 250mgbd, rising to 500mgbd after 4 weeks,
together with hydrocortisone 20mgbd as secondary endo-
crine treatment. Subsequent chemotherapy was according to
current Unit protocols and, in general, the order of priority
was Adriamycin alone, a combination of cyclophosphamide
and methotrexate and 5-fluorouracil (CMF) or a combi-
nation of mitomycin C and vinblastine.
Study parameters
Before entry into the trial, a full physical examination was
performed, measurements were made of all palpable lesions
and visible lesions were photographed. All patients had a
chest radiograph, isotope bone scan with radiographs of
regions of increased uptake, a full blood count and a
biochemical screen. Liver scans were only done if there was a
suspicion of hepatic disease on clinical or biochemical
grounds. Baseline lesions were selected for serial assessment.
Patients were followed up at 4 weekly intervals with repeat
assessment of baseline lesions and, when appropriate, photo-
graphs at each visit. Haematological and biochemical
screens, chest radiographs and bone scans were repeated at
every 3 months.
Response criteria
Objective response was assessed by UICC criteria (Hayward
et al., 1977). Duration of response was dated from the start
of treatment until either new lesions appeared or any one
existing lesion increased by 25% or more above the smallest
size recorded or there was a definite deterioration in evalu-
able, but non-measurable, lesions (photographs or radio-
graphs). These dates were also used for all evaluable patients
to compute curves for time to disease progression. Survival
was from the date of start of treatment to death. Survival
and duration of response were analysed by the log-rank test.
The significance of differences between binary variables was
calculated by the chi-squared test for contingency tables. The
records of patients on this trial were reviewed by an external
assessor.
Results
From 30 November 1981 to 28 August 1986, 220 patients
entered this study. One hundred and ninety-four patients are
evaluable after 26 had been excluded for the following
reasons: at review, 6 patients were found to have been
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ineligible, 2 were lost to follow-up, 7 had had confounding
treatment (6 corticosteroids, 1 interferon), and 11 had inade-
quate information for assessment of response (these patients
are included in the analysis of survival). The minimum
follow-up on any patient was 14 months.
The characteristics of the evaluable patients are shown in
Table I, previous treatments in Table II and sites of disease
at the start of treatment in Table III. These features are well
balanced for the treatment groups according to whether
prednisolone was combined with primary endocrine treat-
Table I Patient characteristics
Treatment group
Pre-menopausal Post-menopausal
O+P O-P T+P T-*P
Total patients assessable 16 15 85 78
Mean age at entry (years) 40 43 63 62
Stage at presentation (no. pts)
I & II (operable) 14 13 67 57
III & IV (advanced) 2 2 18 21
Post-operative disease-free
interval
Median (months) 21 32 20 21
Range 0-86 0-92 0-198 0-248
Time from initial diagnosis
to entry
Median (months) 34 35 36 35
Range 0-100 0-152 0-203 0-248
Steroid receptor statusa
(no. pts)
ER+PgR+ 10 8 43 41
ER+PgR- 3 2 17 20
ER-PgR+ 1 0 2 2
Unknown 2 5 23 15
aWhen this information was available on both primary and
metastatic tumour, that on the latter has been used in the analysis.
Table II Previous treatment
Treatment group
Pre-menopausal Post-menopausal
O+P 0-P T+P T-P
Modified radical mastectomy 12 10 49 51
Excision and radiotherapy 1 3 19 6
Adjuvant chemotherapy 2 0 17 10
Mephalan 0 0 6 3
CMF 2 0 11 7
Primary radiotherapy 2 1 8 5
Alone 2 1 6 3
With chemotherapy 0 0 2 2
Radiotherapy to metastases 6 8 23 26
Table III Sites of disease at start of treatment
Pre-menopa
O+P
Treatment group
zusal Post-menopausal
9 -*P T+P T-P
Skin 7 8 33 26
Breast 4 4 21 21
Lymphatic 4 7 35 32
Bone 6 10 52 49
Lung 3 3 22 17
Pleura 1 3 21 13
Liver 0 0 7 9
Other 0 1 2 4628 D. RUBENS et al.
ment (O +P and T +P) or given sequentially on disease
progression (O-+P and T-.P).
The numbers of patients in each of the response categories
for primary endocrine treatment (O or T) with or without
prednisolone (P) is shown in Table IV. In premenopausal
patients, the response to 0 is increased by the addition of P
(27% vs. 63%; 0.02<P<0.05). Moreover, the median
duration of response is increased from 9 to 20 months
(P=0.02) and the median time to disease progression from 4
to 14 months (P=0.006). In post-menopausal patients, simi-
lar trends were observed. Response frequency to T alone was
31 % and to T +P 46% (0.05 <P <0.l1) while prednisolone sig-
nificantly increased both the median duration of response
(10 vs. 14 months; P=0.02) and the median time to disease
progression (4 vs. 8 months, P =0.02).
Because of the identical clinical objectives of primary
endocrine treatment and the similarity of effects in pre- and
post-menopausal patients, the above results have been com-
bined. Primary endocrine treatment with prednisolone (O+P
and T +P) gives a response frequency of 49/101 (49%), while
without prenidosolone (O and T) it is 28/93 (30%)
(P<0.01). The median duration of response in responding
patients was 9 months for primary endocrine therapy alone
compared to 14 months when combined with prednisolone
(P<0.002; Figure 1) and the median times to disease pro-
gression for patients in these groups were 5 and 9 months
respectively (P<0.001; Figure 2).
The objective regressions at each site of assessable disease
are shown in Table V and there is general tendency for the
responses to be higher in the presence of prednisolone at the
various sites. Response in relation to steroid receptor status
is summarised in Table VI which shows a high overall
response rate for ER +PgR + tumours (46%) and those of
unknown status (44%), but a low rate for ER +PgR-
tumours (19%).
Seventy-two patients who have progressed after primary
endocrine treatment alone have had prednisolone 5 mgbd
prescribed. Sixty-two are assessable of whom only 2 (3%)
achieved an objective regression (both partial responses
lasting 15 + and 22 months). One was pre- and the other
post-menopausal; both had responded to primary endocrine
treatment for 17 and 11 months respectively. Thirty-seven
patients have received aminoglutethimide and hydrocortisone
as secondary endocrine treatment and 7 (19%) achieved an
objective response; 6 had responded to primary endocrine
treatment.
The median survival of patients randomised to receive
prednisolone at the outset of primary endocrine treatment
was significantly increased from 17 to 21 months (P<0.05;
Figure 3). This effect was statistically significant in pre-
menopausal patients (17 vs. 66 months; P=0.04), but not in
post-menopausal (17.5 vs. 21 months, P=0.3).
Primary endocrine treatment either with or without pred-
nisolone was very well tolerated and any side-effects were
mild. Those side-effects probably attributable to treatment
are summarised in Table VII. Weight gain only gave rise to
complaints when prednisolone was prescribed and affected
15% of such patients. Interestingly, hot flushes were more
common in the presence of prednisolone suggesting that this
agent enhances the anti-oestrogenic effect of primary endo-
crine treatment. The incidence of tumour 'flare' and hyper-
calcaemia due to tamoxifen was the same whether or not
prednisolone was given. Prednisolone was added in 3
patients who developed hypercalcaemia on tamoxifen alone.
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Figure 1 Duration of responsc to primary endocrine treatment
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Figure 2 Time to progression of disease after start of primary
endocrine treatment ( with prednisolone; ----- without
prednisolone; P<0.001).
Table V Objective regressions at each site of assessable
diseasea
Treatment group
Pre-menopausal Post-menopausal
O+P 0 T+P T
Skin 5/7 2/8 13/33 8/26
Breast 3/3 1/4 11/22 12/21
Lymphatic 2/4 4/7 20/35 17/30
Bone 4/6 0/8 12/41 6/41
Lung 1/3 0/3 10/21 3/16
Pleura 1/1 0/1 4/15 2/6
Liver 0/0 0/0 1/4 1/9
Other 0/0 0/1 1/2 0/0
aNumerator number of patients with objective regressions
at stated site; denominator=number of patients with assess-
able disease at stated site at start of treatment.
Table IV Numbers of patients in the response categories for primary endocrine treatment
Treatment group
Pre-menopausal Post-menopausal
O+P 0 T+P T
Complete response 2 } 10 (63%) 1 } 4 (27%) 3 39 (46%) 31 24 (31%) Partial response 8 3 34 21
No change 3 5 22 25
Progressive disease 3 6 24 28
I f-I
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Table VI Objective regressions in relation to steroid receptor status
Treatment group
Pre-menopausal Post-menopausal
Receptor phenotype O+P 0 T+P T
ER+PgR+ 7/10 3/8 20/43 17/41
ER+PgR- 1/3 0/2 5/17 2/20
ER-PgR+ 1/1 0/0 1/2 0/2
Unknown 1/2 1/5 13/23 5/15
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Figure 3 Survival from start of primary endocrine treatment
with prednisolone; ----- without prednisolone;
P<0.05).
Table VII Side-effects of treatment
Treatment group
Pre-menopausal Post-menopausal
O+P 0 T+P T
Weight gain 6 0 10 0
Hot flushes 7 1 6 2
Tumour flare 0 0 1 1
Headaches 1 1 1 0
Fluid retention 0 0 5 0
Hypercalcaemia 0 0 4 4
Gastro-intestinal 1 2 4 2
aOther 0 0 5 1
aNocturia, dry mouth, bruising, night cramps.
No patient had to have treatment interrupted or disconti-
nued because of side-effects.
Discussion
The rationale for, and the intention of, endocrine treatment
for breast cancer has been to reduce the oestrogen environ-
ment of the tumour. This can be achieved in various ways
including removing the source of hormones (ovarian abla-
tion) or blocking their receptors (tamoxifen). It is now
apparent that the mechanisms of action of tamoxifen are
more complex than originally thought. A cytostatic effect
has been observed in the complete absence of oestrogen,
suggesting the possibility of receptor mediated anti-growth
factor activity (Vignon et al., 1987). Tamoxifen has also been
shown to induce breast cancer cells to secrete transforming
growth factor-beta which inhibits cell growth (Knabbe et al.,
1987). Such mechanisms could underly the observed efficacy
of tamoxifen as adjuvant treatment in oestrogen receptor
negative tumours (Wilson et al., 1985). Nevertheless, in the
palliation of advanced breast cancer, response to tamoxifen
is uncommon with receptor negative tumours (Stewart et al.,
1982) and rare in non-hormone-dependent cancers (Jackson
& Lowery, 1987). Hence the prime objective of endocrine
treatment for advanced breast cancer still seems to be a
lowering of the tumour's oestrogen status which currently is
best achieved by ovarian ablation in pre-menopausal and
tamoxifen in post-menopausal patients. These treatments
give similar results and combining these menstrual subsets as
primary endocrine treatment in this trial was considered
valid.
The results reaffirm those of the previous trial (Stewart et
al., 1982) and show that the addition of prednisolone to
primary endocrine treatment significantly increases the re-
sponse frequency from an expected 30% to 49%. The
duration of response and survival are also increased and
particularly significant in pre-menopausal patients. The re-
sponse to prednisolone after failure of primary endocrine
treatment alone was poor. Response to aminoglutethimide as
secondary endocrine treatment was lower than expected, but
the gain achieved by combining prednisolone with initial
endocrine therapy is not outweighed as shown by the
survival data. Unlike the previous trial, prednisolone did not
prevent hypercalcaemia or tumour 'flare'.
The mechanism of action of prednisolone is uncertain, but
the larger number of patients experiencing hot flushes when
this agent was used suggests that it acts, at least in part, by
enhancing the anti-oestrogenic effect of treatment. In the
previous trial, it was shown that prednisolone had a marked,
and expected, inhibitory effect on serum dehydro-
epiandrosterone sulphate levels and it also marginally
reduced the levels of serum oestradiol in post-menopausal
women receiving tamoxifen (Blackburn et al., 1984). Predni-
solone had no effect on the serum levels of luteinising
hormone, follicular stimulating hormone or prolactin.
Because of the recent interest in the role of free-oestradiol in
the aetiology and clinical course of breast cancer and its
availability reflected in serum levels of sex hormone binding
globulin (SHBG), SHGB levels in the stored sera of patients
in the previous trial have been studied (Wang et al., 1988).
In pre-menopausal patients, prednisolone had no effect on
the reduction in SHGB levels seen after ovarian ablation. In
post-menopausal patients, tamoxifen led to a rapid rise in
SHBG levels, but this was markedly dampened by predniso-
lone. Hence, although treatment by ovarian ablation and
tamoxifen is designed to reduce oestrogen status in women
with metastatic breast cancer, the action of prednisolone on
SHBG would not appear to contribute to this effect.
Two clinical trials have now shown that prednisolone
improves the response to primary endocrine treatment and
this is achieved without significant side effects. The mecha-
nism of action is not known, but is probably complex
involving effects on both oestrogen status and directly on the
cancer cell. The optimal dose of prednisolone is not known,
but higher doses than used here would probably lead to an
unacceptable incidence of adverse effects. We now routinely
prescribe prednisolone with ovarian ablation in pre-
menopausal, and tamoxifen in post-menopausal, patients for
the treatment of metastatic breast cancer, provided that there
are no contra-indications to corticosteroids.
We are grateful to Dr R. J. B. King for the steroid receptor
analyses, Professor N. Gad-el-Mawla for reviewing the clinical
records and Miss Z. Doran for help with data retrieval.630 D. RUBENS et al.
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